AstraZeneca plans to apply for regulatory approval for Blood Pressure Drug Baxdrostat before the end of this year, with approval expected in the U.S. and E.U. in 2026. The company views the opportunity in Baxdrostat as the crux of its strategy...
Mahajan Imaging & Labs, a pioneer in integrated diagnostics and advanced medical imaging, has entered a strategic alliance with Fortis La Femme, India’s leading hospital dedicated to women’s and children’s health, to create a new benchmark in...
Eli Lilly and Company announced positive top-line results in the Phase 3 ATTAIN-2 trial that evaluated, orforglipron, an investigational oral GLP-1 receptor agonist in adults with obesity or overweight and type 2 diabetes. The ATTAIN-2 trial showed
Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd., has announced the FDA approval and U.S. market availability of the first generic version of Saxenda
MedGenome unveiled the first CNS Tumour Methylation Classifier Test in India, which is a futuristic diagnostic tool that can recognize and categorize
Health Canada has licensed Ozempic (semaglutide injection) as the first-and-only drug to be used for once-weekly treatment of type 2 diabetes (T2D) and for the reduction of the risk of progression of kidney disease, end-stage kidney di...
A new treatment by Pfizer’s Padcev and Merck’s Keytruda is showing positive results in patients with advanced bladder cancer. A recent study looked at these two drugs combined and showed that they helped patients live longer and delayed...
L V Prasad Eye Institute (LVPEI) is recognised as one of the forefront global centres for corneal neurotization surgery that has performed over 40 surgeries with surgical success rates similar to other established centres worldwide.
Meril, a global leader in advanced medical solutions, brought together some of India’s most distinguished oncology experts at OncoXchange, a high-impact panel discussion held at Meril Academy, Aloft Hotel, Aerocity, New Delhi.
.jpeg)
India’s biopharmaceutical sector is witnessing a significant shift as Biocon intensifies its dual focus on insulin and GLP-1 therapies, positioning itself strongly in two high-growth segments. With decades of expertise in biosimilar insulins, the Ben
.jpg)
, CDSCO.jpg)